These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 6938045)

  • 21. The nonsteroidal effects of diethylstilbestrol: the rationale for androgen deprivation therapy without estrogen deprivation in the treatment of prostate cancer.
    Scherr DS; Pitts WR
    J Urol; 2003 Nov; 170(5):1703-8. PubMed ID: 14532759
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of endocrine therapy in the management of local and distant recurrence of prostate cancer following radical prostatectomy or radiation therapy.
    Mayer FJ; Crawford ED
    Urol Clin North Am; 1994 Nov; 21(4):707-15. PubMed ID: 7974899
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of parenteral polyestradiol phosphate in the treatment of advanced prostatic cancer on the threshold of the new millennium.
    Mikkola A; Ruutu M; Aro J; Rannikko S; Salo J
    Ann Chir Gynaecol; 1999; 88(1):18-21. PubMed ID: 10230677
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [How should patients with prostate cancer be treated?].
    Hvidt V
    Ugeskr Laeger; 1977 Feb; 139(9):543-4. PubMed ID: 841747
    [No Abstract]   [Full Text] [Related]  

  • 25. "Just Another Statistic".
    Machtay M; Glatstein E
    Oncologist; 1998; 3(3):III-IV. PubMed ID: 10388105
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neoadjuvant hormonal deprivation in locally advanced prostate cancer: does it make sense?
    Schulman CC; Wildschutz TP
    Acta Urol Belg; 1996 May; 64(2):57-61. PubMed ID: 8701814
    [No Abstract]   [Full Text] [Related]  

  • 27. [Influence of cardiovascular risk on survival in prostatic cancers stage C or D treated with high dose estrogen. Apropos of 170 cases].
    Burte R; Amiel J; Benoliel J; Raymond G; Toubol J
    J Urol (Paris); 1986; 92(4):252-3. PubMed ID: 3782833
    [No Abstract]   [Full Text] [Related]  

  • 28. Estrogen and survival data in carcinoma of the prostate.
    Bennett AH; Dowd JB; Harrison JH
    Surg Gynecol Obstet; 1970 Mar; 130(3):505-8. PubMed ID: 4905115
    [No Abstract]   [Full Text] [Related]  

  • 29. [Clinical study of prostatic cancer--statistical analysis of 184 cases in the latest 21 years].
    Yamashita A; Hayashi N; Sugimura Y; Yanagawa M; Arima K; Nakano S; Kimbara H; Tochigi H; Kawamura J
    Hinyokika Kiyo; 1995 Jun; 41(6):447-53. PubMed ID: 7645452
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hormone therapy in prostatic cancer.
    Smith PH; Akdas A; Mason MK; Richards B; Robinson MR; de Pauw M; Sylvester R
    Acta Urol Belg; 1980 Jan; 48(1):98-105. PubMed ID: 7001876
    [No Abstract]   [Full Text] [Related]  

  • 31. Understanding treatments for bone loss and bone metastases in patients with prostate cancer: a practical review and guide for the clinician.
    Higano CS
    Urol Clin North Am; 2004 May; 31(2):331-52. PubMed ID: 15123412
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hypophysectomy in metastatic prostrate cancer.
    Thompson JB; Greenberg E; Pazianos A; Pearson OH
    N Y State J Med; 1974 Jun; 74(6):1006-8. PubMed ID: 4525691
    [No Abstract]   [Full Text] [Related]  

  • 33. Hormone replacement therapy in the post-Women's Health Initiative era. Report a a meeting held in Funchal, Madeira, February 24-25, 2003.
    Burger H
    Climacteric; 2003 May; 6 Suppl 1():11-36. PubMed ID: 12945798
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The choice of treatment for cancer patients based on covariate information.
    Byar DP; Green SB
    Bull Cancer; 1980; 67(4):477-90. PubMed ID: 7013866
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Breast cancer as a second primary in patients with prostate cancer--estrogen treatment or association with family history of cancer?
    Karlsson CT; Malmer B; Wiklund F; Grönberg H
    J Urol; 2006 Aug; 176(2):538-43. PubMed ID: 16813884
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Unresolved questions in hormonal therapy for prostate cancer].
    Oishi K
    Gan To Kagaku Ryoho; 1994 Sep; 21(12):1928-33. PubMed ID: 8085843
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer: part 2. Final evaluation of the Scandinavian Prostatic Cancer Group (SPCG) Study No. 5.
    Hedlund PO; Damber JE; Hagerman I; Haukaas S; Henriksson P; Iversen P; Johansson R; Klarskov P; Lundbeck F; Rasmussen F; Varenhorst E; Viitanen J;
    Scand J Urol Nephrol; 2008; 42(3):220-9. PubMed ID: 18432528
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Current aspects of hormonal therapy in prostate cancer].
    Altwein JE
    Helv Chir Acta; 1981 Aug; 48(3-4):391-5. PubMed ID: 7287476
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Proceedings: conservative management of prostatic cancer.
    Straffon WG
    Br J Urol; 1975 Apr; 47(2):227-8. PubMed ID: 807284
    [No Abstract]   [Full Text] [Related]  

  • 40. [Estrogen treatment of prostatic cancer after total prostatectomy: rates of survival and cardiovascular complications in the Mellinger-Belt series].
    Belt E; Schröder FH
    Urologe; 1971 Mar; 10(2):56-8. PubMed ID: 5577978
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.